Skip to main content
Fig. 2 | Journal of Nanobiotechnology

Fig. 2

From: Lipoplex-based targeted gene therapy for the suppression of tumours with VEGFR expression by producing anti-angiogenic molecules

Fig. 2

The binding activities of the LPPC/DiO/RBDV-IgG1 Fc complexes. a BALB/3T3 cells and b B16-F10 cells were stained with DiO-labelled LPPC complexes without PEG 1.500 complexed. c BALB/3T3 cells and d B16-F10 cells were stained with PEG-complexed LPPC/DiO complexes. e DiO-labelled LPPC complexes (50 μg) were incubated with different amounts of RBDV-IgG1 Fc or IgG1 Fc proteins for 30 min, and then the complexes were added to B16-F10 cells. The binding intensity was analysed by flow cytometry. The data represent the mean ± SD (n = 6). Significant differences are evaluated by Student’s t-test and are labelled as *P < 0.05

Back to article page